A Retrospective Study for the Limited-stage Small Cell Lung Cancer Patients with Combined Modality Treatment:An Analysis of 234 Patients
- VernacularTitle:234例局限期小细胞肺癌综合治疗结果分析
- Author:
Zongmei ZHOU
;
Dongfu CHEN
;
LvHua WANG
;
Jun LIANG
;
Kai WANG
;
Shiping ZHANG
;
Zefen XIAO
;
Hongxin ZHANG
;
Qinfu FENG
;
Guangfei OU
;
Xiangru ZHANG
;
Weibo YIN
- Publication Type:Journal Article
- Keywords:
Carcinoma;
Small cell;
Carcinoma;
Small cell lung/radiotherapy;
Carcinoma;
Small cell lung/chemotherapy;
Combined modality therapy
- From:
Journal of Medical Research
2006;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the treatment effects of chemotherapy comparing with chemotherapy and radiotherapy in the limited-stage small cell lung cancer (SCLC). Methods 234 patients were cyto-pathologically diagnosed and staged as limited small cell lung cancer. The patients were treated with combined chemotherapy and radiotherapy,in which 22 cases were treated by alone chemotherapy (C),39 patients by chemotherapy plus radiotherapy(C+R),and 173 cases by combined chemotherapy and radiotherapy + chemotherapy (C+R+C). The chemotherapy regimen included CE (or PE),CAP or CAV for 4~6 cycles. Irradiation treatment covering the primary tumor,the ipsilateral hilar nodes and mediastinum was delivered once daily with 6 megavoltage X-ray beam to a median irradiation does of 56 Gy being given in 5~6 weeks. Results The 1-,2-,3-,and 5-year overall survival rates were 76.5%,38.2%,25.3%,15.6% respectively,and the median survival time (MST) was 19 months. There was a significantly difference on the survival rate between C+R+C group and C+R group or C group (P
